Drs Gail Roboz and Alexander Perl discuss adverse-risk acute myeloid leukemia.
Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/964535). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.
Resources
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study https://ascopubs.org/doi/10.1200/JCO.2012.45.9628
Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291965/
The Presence of a FLT3 Internal Tandem Duplication in Patients With Acute Myeloid Leukemia (AML) Adds Important Prognostic Information to Cytogenetic Risk Group and Response to the First Cycle of Chemotherapy: Analysis of 854 Patients From the United Kingdom Medical Research Council AML 10 and 12 trials https://www.sciencedirect.com/science/article/pii/S0006497120609351?via%3Dihub
Diagnostic and Therapeutic Pitfalls in NPM1-Mutated AML: Notes From the Field https://www.nature.com/articles/s41375-021-01222-4
Prognostic Impact of DNMT3A Mutation in Acute Myeloid Leukemia With Mutated NPM1 https://www.sciencedirect.com/science/article/pii/S2473952921005425
Midostaurin Plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754190/pdf/nihms901401.pdf
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First) https://clinicaltrials.gov/ct2/show/NCT02668653
A Review of FLT3 Inhibitors in Acute Myeloid Leukemia https://www.sciencedirect.com/science/article/abs/pii/S0268960X21001119?via%3Dihub
Abstract 591: Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16) https://ash.confex.com/ash/2020/webprogram/Paper137334.html
AC220 Is a Uniquely Potent and Selective Inhibitor of FLT3 for the Treatment of Acute Myeloid Leukemia (AML) https://news.unboundmedicine.com/medline/citation/19654408/AC220_is_a_uniquely_potent_and_selective_inhibitor_of_FLT3_for_the_treatment_of_acute_myeloid_leukemia__AML__
Daiichi Waits on FDA as AML Drug Quizartinib Approved in Japan https://pharmaphorum.com/news/daiichi-waits-on-fda-as-aml-drug-quizartinib-approved-in-japan/
FDA Declines to Approve Quizartinib for FLT3-Mutated Acute Myeloid Leukemia https://ashpublications.org/ashclinicalnews/news/4584/FDA-Declines-to-Approve-Quizartinib-for-FLT3
Safety and Preliminary Efficacy of Venetoclax With Decitabine or Azacitidine in Elderly Patients With Previously Untreated Acute Myeloid Leukaemia: A Non-randomised, Open-Label, Phase 1b Study https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30010-X/fulltext
Triplet Therapy With Venetoclax, FLT3 Inhibitor and Decitabine for FLT3-Mutated Acute Myeloid Leukemia https://www.nature.com/articles/s41408-021-00410-w
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients With Acute Myeloid Leukemia and IDH1/2 Mutations https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-21-3467/677977/Impact-of-Venetoclax-and-Azacitidine-in-Treatment
Abstract 32: Comparing Outcomes Between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia https://ash.confex.com/ash/2021/webprogram/Paper145947.html
Abstract 795: Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia https://ash.confex.com/ash/2021/webprogram/Paper149158.html
